NCT03815682

RPTR-147 in Patients With Selected Solid Tumors and Lymphomas

A Phase 1/2 Study of Deep IL-15 Loaded T-Cells Alone and in Combination With Pembrolizumab in Patients With Select Solid Tumors and Lymphomas

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Repertoire Immune Medicines · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety and tolerability of escalating doses of RPTR-147 as a monotherapy and in combination with Pembrolizumab in patients with selected solid tumors and lymphomas.

Detailed description

This is a first-in-human, open-label, multicenter, dose escalation study designed to determine the safety and tolerability of RPTR-147 as a monotherapy and in combination with Pembrolizumab in patients with selected solid tumors or lymphomas. The study will include 2 dosing periods: A Dose Escalation (Phase 1) followed by an Expansion (Phase 2).

Conditions

• Solid Tumor
• Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	Arm A: RPTR-147:1	Escalating doses of RPTR-147:1 as a monotherapy
BIOLOGICAL	Arm B: RPTR-147:1 and Pembrolizumab	Escalating doses of RPTR-147:1 in combination with Pembrolizumab
BIOLOGICAL	Arm C: RPTR-147:2	Escalating doses of RPTR-147:2 in patients with HPV positive tumors

Timeline

• Start date: 2018-10-24
• Primary completion: 2022-09-07
• Completion: 2022-10-11
• First posted: 2019-01-24
• Last updated: 2022-12-06

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study